Ask AI

From Pathway to Patient: Making Sense of TYK2 Inhibition in Real-world Plaque Psoriasis Decisions

Explore the persistent, unmet needs in plaque psoriasis care, understand the evolving role of oral small molecule therapies, including the differences in TYK2 and JAK pathway targeting, and take home strategies for developing guideline-concordant, patient-centered care plans through expert-written ClinicalThought commentaries, downloadable slides, and a text module.

Share

Program Content

Events

  • Live Event
    From Pathway to Patient: Making Sense of TYK2 Inhibition in Real-world Plaque Psoriasis Decisions
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

TYK2 inhibition in plaque psoriasis
TYK2 Inhibition in Plaque Psoriasis: Biologic Rationale and Recent Findings From AAD 2026
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2026

Expires: September 30, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.